Table 3.

SOT recipient demographics and disease characteristics

Age, y	Sex	SOT	Age at transplant	Graft rejection prophylaxis	Clinical concern	BKPyV treatment before VSTs	Pre-VST viremia, copies/mL	No. TP-VST given	Therapy outcome
16	Male	Heart	11 y	Everolimus	EBV/PTLD CKD BK viremia	Leflunomide Cidofovir IVIG IST reduction (CHOP for PTLD)	BKPyV: 12 000 000 EVB: 132 000	3	BKPyV: PR EBV: cleared EBV viremia and resolved PTLD on PET scan
10	Male	Heart and kidney	Heart: 1 mo Kidney: 4 y	Tacrolimus + prednisone	EBV and BK viremia and history of nephropathy in first kidney transplant	Cidofovir Leflunomide IVIG IST reduction	BK: 1 000 EBV: 15 000	10	BK: cleared EBV: cleared. Received second kidney transplant, no graft rejection
10	Female	Kidney	9 y	Tacrolimus	Persistent BK viremia	Cidofovir, leflunomide IVIG IST reduction	BK: 9 700	1	BK viremia reduced 2000 copies/mL, no graft rejection

CHOP, cyclophosphamide, doxorubicin, vincristine, prednisolone; IST, immunosuppressive therapy; PET, positron emission tomography; TP-VSTs, third-party donor VSTs.